US87650L1035
US87650L1035
Tarsus Pharmaceuticals, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 451.360.000 | 182.953.000 | 146.7% |
| Cost of Revenue | 30.684.000 | 12.826.000 | 139.2% |
| Gross Profit | 420.676.000 | 170.127.000 | 147.3% |
| 491.645.000 | 290.696.000 | 69.1% | |
| Operating Income | -70.969.000 | -120.569.000 | 41.1% |
| Pretax Income | -64.359.000 | -115.554.000 | 44.3% |
| Net Income Common Stockholders | -66.418.000 | -115.554.000 | 42.5% |
| -- | -- | -- | |
| -- | -- | -- |